Early results from an open-label phase 1b/II study of eribulin mesylate (EM) + pegvorhyaluronidase alfa (PEGHP20) combination for the treatment of patients with HER2-negative, high-hyaluronan (HA) metastatic breast cancer (MBC)

Early results from an open-label phase 1b/II study of eribulin mesylate (EM) + pegvorhyaluronidase alfa (PEGHP20) combination for the treatment of patients with HER2-negative, high-hyaluronan (HA) metastatic breast cancer (MBC)

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of oncology 2018-10, Vol.29, p.viii99-viii99
Hauptverfasser: Shum, M., Assikis, V.J., Savulsky, C., Zhu, W., Iyer, P., Xing, D., Berman, C., Lokker, N.A., Alvarez, R.H.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page viii99
container_issue
container_start_page viii99
container_title Annals of oncology
container_volume 29
creator Shum, M.
Assikis, V.J.
Savulsky, C.
Zhu, W.
Iyer, P.
Xing, D.
Berman, C.
Lokker, N.A.
Alvarez, R.H.
description
doi_str_mv 10.1093/annonc/mdy272.301
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdy272_301</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753419487309</els_id><sourcerecordid>32138141</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2301-e44e7bbf0929875f89570d9c8af4f14898176df8ad7042d97fddc3c10c0c82dd3</originalsourceid><addsrcrecordid>eNp9UcGO0zAUjBCILQsfwAW9YyvI1k7SJtaelipsK-2KFYJz5NjPjVFiR7ZTlO_lR3BVliOnZz3PzBvNJMl7Sm4oYfmaG2ONWA9yzsrsJif0RbKgmy1LK1LQl8mCsCxPy01eXCVvvP9JCNmyjL1OrvKM5hUt6CL5XXPXz-DQT33woJwdgBuwI5q05y32MHbcI9B2fTiAD5OcwSpAp9up1wYG9HPPA8KyflzBRxjxeLKum3k_OWu0PHN5rzgsn-r7_VNGViDs0GrDg7YGlHUQOoTgkIcBTTiLj_EvPj380qGDff0tSw0e4_KEn6DTxy591o9Ol_u7VXQRuA8RIaCNSj6A4Eagg-Xj593qbfJK8d7ju7_zOvnxpf6-26cPX-8Pu7uHVGQxuxSLAsu2VTE1VpUbVbFNSSQTFVeFokXFKlpupaq4LEmRSVYqKUUuKBFEVJmU-XVCL7rCWe8dqmZ0euBubihpzoU1l8KaS2FNPBo5Hy6ccWoHlP8Yzw1FwO0FgNH5SaNrvIjpCJTaoQiNtPo_8n8AuAeq_g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Early results from an open-label phase 1b/II study of eribulin mesylate (EM) + pegvorhyaluronidase alfa (PEGHP20) combination for the treatment of patients with HER2-negative, high-hyaluronan (HA) metastatic breast cancer (MBC)</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Shum, M. ; Assikis, V.J. ; Savulsky, C. ; Zhu, W. ; Iyer, P. ; Xing, D. ; Berman, C. ; Lokker, N.A. ; Alvarez, R.H.</creator><creatorcontrib>Shum, M. ; Assikis, V.J. ; Savulsky, C. ; Zhu, W. ; Iyer, P. ; Xing, D. ; Berman, C. ; Lokker, N.A. ; Alvarez, R.H.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdy272.301</identifier><identifier>PMID: 32138141</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><ispartof>Annals of oncology, 2018-10, Vol.29, p.viii99-viii99</ispartof><rights>2018 THE AUTHORS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32138141$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shum, M.</creatorcontrib><creatorcontrib>Assikis, V.J.</creatorcontrib><creatorcontrib>Savulsky, C.</creatorcontrib><creatorcontrib>Zhu, W.</creatorcontrib><creatorcontrib>Iyer, P.</creatorcontrib><creatorcontrib>Xing, D.</creatorcontrib><creatorcontrib>Berman, C.</creatorcontrib><creatorcontrib>Lokker, N.A.</creatorcontrib><creatorcontrib>Alvarez, R.H.</creatorcontrib><title>Early results from an open-label phase 1b/II study of eribulin mesylate (EM) + pegvorhyaluronidase alfa (PEGHP20) combination for the treatment of patients with HER2-negative, high-hyaluronan (HA) metastatic breast cancer (MBC)</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9UcGO0zAUjBCILQsfwAW9YyvI1k7SJtaelipsK-2KFYJz5NjPjVFiR7ZTlO_lR3BVliOnZz3PzBvNJMl7Sm4oYfmaG2ONWA9yzsrsJif0RbKgmy1LK1LQl8mCsCxPy01eXCVvvP9JCNmyjL1OrvKM5hUt6CL5XXPXz-DQT33woJwdgBuwI5q05y32MHbcI9B2fTiAD5OcwSpAp9up1wYG9HPPA8KyflzBRxjxeLKum3k_OWu0PHN5rzgsn-r7_VNGViDs0GrDg7YGlHUQOoTgkIcBTTiLj_EvPj380qGDff0tSw0e4_KEn6DTxy591o9Ol_u7VXQRuA8RIaCNSj6A4Eagg-Xj593qbfJK8d7ju7_zOvnxpf6-26cPX-8Pu7uHVGQxuxSLAsu2VTE1VpUbVbFNSSQTFVeFokXFKlpupaq4LEmRSVYqKUUuKBFEVJmU-XVCL7rCWe8dqmZ0euBubihpzoU1l8KaS2FNPBo5Hy6ccWoHlP8Yzw1FwO0FgNH5SaNrvIjpCJTaoQiNtPo_8n8AuAeq_g</recordid><startdate>201810</startdate><enddate>201810</enddate><creator>Shum, M.</creator><creator>Assikis, V.J.</creator><creator>Savulsky, C.</creator><creator>Zhu, W.</creator><creator>Iyer, P.</creator><creator>Xing, D.</creator><creator>Berman, C.</creator><creator>Lokker, N.A.</creator><creator>Alvarez, R.H.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201810</creationdate><title>Early results from an open-label phase 1b/II study of eribulin mesylate (EM) + pegvorhyaluronidase alfa (PEGHP20) combination for the treatment of patients with HER2-negative, high-hyaluronan (HA) metastatic breast cancer (MBC)</title><author>Shum, M. ; Assikis, V.J. ; Savulsky, C. ; Zhu, W. ; Iyer, P. ; Xing, D. ; Berman, C. ; Lokker, N.A. ; Alvarez, R.H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2301-e44e7bbf0929875f89570d9c8af4f14898176df8ad7042d97fddc3c10c0c82dd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shum, M.</creatorcontrib><creatorcontrib>Assikis, V.J.</creatorcontrib><creatorcontrib>Savulsky, C.</creatorcontrib><creatorcontrib>Zhu, W.</creatorcontrib><creatorcontrib>Iyer, P.</creatorcontrib><creatorcontrib>Xing, D.</creatorcontrib><creatorcontrib>Berman, C.</creatorcontrib><creatorcontrib>Lokker, N.A.</creatorcontrib><creatorcontrib>Alvarez, R.H.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shum, M.</au><au>Assikis, V.J.</au><au>Savulsky, C.</au><au>Zhu, W.</au><au>Iyer, P.</au><au>Xing, D.</au><au>Berman, C.</au><au>Lokker, N.A.</au><au>Alvarez, R.H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Early results from an open-label phase 1b/II study of eribulin mesylate (EM) + pegvorhyaluronidase alfa (PEGHP20) combination for the treatment of patients with HER2-negative, high-hyaluronan (HA) metastatic breast cancer (MBC)</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2018-10</date><risdate>2018</risdate><volume>29</volume><spage>viii99</spage><epage>viii99</epage><pages>viii99-viii99</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><cop>England</cop><pub>Elsevier Ltd</pub><pmid>32138141</pmid><doi>10.1093/annonc/mdy272.301</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0923-7534
ispartof Annals of oncology, 2018-10, Vol.29, p.viii99-viii99
issn 0923-7534
1569-8041
language eng
recordid cdi_crossref_primary_10_1093_annonc_mdy272_301
source EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
title Early results from an open-label phase 1b/II study of eribulin mesylate (EM) + pegvorhyaluronidase alfa (PEGHP20) combination for the treatment of patients with HER2-negative, high-hyaluronan (HA) metastatic breast cancer (MBC)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T17%3A59%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Early%20results%20from%20an%20open-label%20phase%201b/II%20study%20of%20eribulin%20mesylate%20(EM)%20+%20pegvorhyaluronidase%20alfa%20(PEGHP20)%20combination%20for%20the%20treatment%20of%20patients%20with%20HER2-negative,%20high-hyaluronan%20(HA)%20metastatic%20breast%20cancer%20(MBC)&rft.jtitle=Annals%20of%20oncology&rft.au=Shum,%20M.&rft.date=2018-10&rft.volume=29&rft.spage=viii99&rft.epage=viii99&rft.pages=viii99-viii99&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdy272.301&rft_dat=%3Cpubmed_cross%3E32138141%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32138141&rft_els_id=S0923753419487309&rfr_iscdi=true